Molecular Med TRI-CON, 11–16 February 2018, San Francisco, USA

Meeting Report
  • 9 Downloads

Notes

Acknowledgements

The author would like to thank Molecular Med TRI-CON for the opportunity to attend this conference.

Compliance with ethical standards

Conflict of interest

The author (AF) has no potential conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, Georgiadis A, Phallen J, Brahmer J, Azad N, Browner I, Laheru D, Velculescu VE, Sausen M, Diaz LA Jr. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23(10):2471–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Tiran V, Lindenmann J, Brcic L, Heitzer E, Stanzer S, Tabrizi-Wizsy NG, Stacher E, Stoeger H, Popper HH, Balic M, Dandachi N. Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition. Sci Rep. 2017;7(1):10040.  https://doi.org/10.1038/s41598-017-09929-0.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH, El-Ashry D. Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 2015;75(22):4681–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J. Clinical significance of androgen receptor splice variant-7 mrna detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56.CrossRefPubMedGoogle Scholar
  5. 5.
    Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017;77(16):4238–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, Chan G, Hui EP, Ma BBY, Chiu RWK, Leung SF, van Hasselt AC, Chan ATC, Lo YMD. Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee I, Baxter D, Lee MY, Scherler K, Wang K. The importance of standardization on analyzing circulating RNA. Mol Diagn Ther. 2017;21(3):259–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AM, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget. 2016;7(1):1066–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Adis Journals, Springer HealthcareAucklandNew Zealand

Personalised recommendations